Cryoport vs Kamada
CYRX and KMDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYRX and KMDA compare
Kamada grew revenue faster over the last twelve months (13.2% versus 11.8% for Cryoport).
Cryoport scores higher on the StockData Score (10 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYRX | KMDA |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | – |
| Share price | $19.89 | $8.09 |
| Change, 1 year | 125% | 11.1% |
| Change, 5 years | −72.5% | 44.5% |
| Beta (5Y) | 1.92 | 0.76 |
| Employees | 738 | 393 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 0 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.2× | – |
| P/B | 2.1× | – |
| FCF yield | −1.9% | – |
| Fair value | $15.89 | – |
| Margin of safety | −25.2% | – |
| Growth | ||
| Revenue growth (TTM) | 11.8% | 13.2% (better) |
| Revenue growth, 5Y average | 17.5% (better) | 6.3% |
| Net income growth (TTM) | −158% | – |
| EPS growth (TTM) | −178% | – |
| EPS growth, 5Y average | – | −1.6% |
| Profitability | ||
| Gross margin | 46.9% (better) | 40.8% |
| Operating margin | −20.0% | 14.5% (better) |
| Net margin | −21.5% | – |
| FCF margin | −9.8% | – |
| Return on equity | −8.3% | – |
| Return on invested capital | −32.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | −0.54 |
| Interest coverage | −18.3× | 26.8× (better) |
| Current ratio | 2.04 | 4.06 (better) |
| Altman Z-score | 1.38 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 93.9% | 8.6% |
| Held by insiders | 3.6% | 45.3% |
| Insider net buying, 12 months | −$6.3M | −$1.7M (better) |
| Short interest, % of float | 7.1% | 0.53% |
Go deeper
- CYRX stock overview
- CYRX income statement
- CYRX valuation and score
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.